AstraZeneca Plc FDA requested trial data for saxagliptin to investigate potential association with heart failure - press
- Expected to submit trial data by early March.
- Published study that reported higher rate of hospitalization for heart failure with use of saxagliptin did not find higher rates of death or other major cardiovascular risks, including heart attack or stroke, in patients on saxagliptin.
*** AZN purchased Bristol-Myers global diabetes alliance assets for an initial consideration of $2.7B in Dec. Upon completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, which includes Onglyza(saxagliptin), KombiglyzeXR (saxagliptin and metformin HCl extended release), Komboglyze(saxagliptin and metformin HCl), dapagliflozin (marketed as Forxigaoutside the US), Byetta(exenatide), Bydureon(exenatide extended-release for injectable suspension), metreleptin and Symlin(pramlintide acetate).